High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Liebrenz, Michael ^a   Hof, Danielle ^b   Buadze, Anna ^a   Stohler, Rudolf ^a   Eich, Dominique ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; METHYLPHENIDATE;

ADULT; ADULT DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL;

EID: 84860825818     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-125     Document Type: Article

References (26)

1. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al. Am J Psychiatry 2006 163 716 723 10.1176/appi.ajp.163.4.716 16585449 (Pubitemid 44464584)
2. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A, Am J Psychiatry 1993 150 1792 1798 8238632 (Pubitemid 23356570)
3. Diagnosing and treating attention-deficit/hyperactivity disorder in adults. Faraone SV, Antshel KM, World Psychiatry 2008 7 131 136 18836579
4. Attention deficit hyperactivity disorder in adults. Rosler M, Casas M, Konofal E, Buitelaar J, World J Biol Psychiatry 2010 11 684 698 10.3109/15622975.2010.483249 20521876
5. Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride. Nair R, Moss SB, Neuropsychiatr Dis Treat 2009 5 421 432 19721722
6. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. Barkley RA, Brown TE, CNS Spectr 2008 13 977 984 19037178
7. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Harpin VA, Arch Dis Child Educ Pract Ed 2008 93 58 65 10.1136/adc.2006.106864 18356307 (Pubitemid 352039424)
8. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J, J Clin Psychopharmacol 2004 24 24 29 10.1097/01.jcp. 0000108984.11879.95 14709943 (Pubitemid 38134162)
9. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL, Synapse 2006 59 243 251 10.1002/syn.20235 16385551 (Pubitemid 43202592)
10. Effects of methylphenidate: the cellular point of view. Bartl J, Link P, Schlosser C, Gerlach M, Schmitt A, Walitza S, Riederer P, Grunblatt E, Atten Defic Hyperact Disord 2010 2 225 232 10.1007/s12402-010-0039-6 21432609
11. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer TJ, BMC Psychiatry 2007 7 49 10.1186/1471-244X-7-49 17868455 (Pubitemid 350111687)
12. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Pliszka S, J Am Acad Child Adolesc Psychiatry 2007 46 894 921 17581453
13. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. Kendall T, Taylor E, Perez A, Taylor C, BMJ Clinical research ed 2008 337 1239 10.1136/bmj.a1239 18815170
14. Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. Doerge DR, Fogle CM, Paule MG, McCullagh M, Bajic S, Rapid Commun Mass Spectrom 2000 14 619 623 10.1002/(SICI)1097-0231(20000430)14:8<619::AID-RCM916>3.0. CO;2-2 10786896 (Pubitemid 30217998)
15. Pharmacokinetic and Pharmacodynamic Properties of Methylphenidate in Humans. Swanson J, Volkow N, Stimulant drugs and ADHD Oxford University Press, New York, Solanto M, Arnsten A, Castellanos FX, 2001 259 282
16. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF, J Pharmacol Exp Ther 2004 310 469 476 10.1124/jpet.104.067116 15082749 (Pubitemid 38988889)
17. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, et al. Am J Hum Genet 2008 82 1241 1248 10.1016/j.ajhg.2008.04.015 18485328
18. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M, Neuropharmacology 2009 57 731 733 10.1016/j.neuropharm.2009.08.014 19733552
19. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, et al. JAMA 2011 306 2673 2683 10.1001/jama.2011.1830 22161946
20. Adult Attention-Deficit/Hyperactivity Disorder Treatment and Cardiovascular Implications. Hammerness PG, Surman CB, Chilton A, Curr Psychiatry Rep 2011 13 357 363 10.1007/s11920-011-0213-3 21698412
21. Methylphenidate-induced hepatotoxicity in mice and its potentiation by beta-adrenergic agonist drugs. Roberts SM, Harbison RD, Roth L, James RC, Life Sci 1994 55 269 281 10.1016/0024-3205(94)00729-2 7913199
22. Hepatotoxicity due to methylphenidate hydrochloride. Goodman CR, N Y State J Med 1972 72 2339 2340 4506888
23. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. Winhusen TM, Lewis DF, Riggs PD, Davies RD, Adler LA, Sonne S, Somoza EC, J Child Adolesc Psychopharmacol 2011 21 455 463 10.1089/cap.2011.0014 22040190
24. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. Klein-Schwartz W, McGrath J, J Am Acad Child Adolesc Psychiatry 2003 42 288 294 10.1097/00004583-200303000-00008 12595781 (Pubitemid 39592084)
25. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Bruggisser M, Bodmer M, Liechti ME, Swiss Med Wkly 2011 141 13267 21984207
26. Case report: intoxication with high dose of long-acting methylphenidate (Concerta((R))) in a suicidal 14-year-old girl. Klampfl K, Quattlander A, Burger R, Pfuhlmann B, Warnke A, Gerlach M, Atten Defic Hyperact Disord 2010 2 221 224 10.1007/s12402-010-0032-0 21432608